<p>This full educational program can be accessed at no cost here: <a href="https://annenberg.net/courses/landingPage.php?courseID=61030" target="_blank" rel="ugc noopener noreferrer">https://annenberg.net/courses/landingPage.php?courseID=61030</a></p>

This full educational program can be accessed at no cost here: https://annenberg.net/courses/landingPage.php?courseID=61030

<p>This full educational program can be accessed at no cost here: <a href="https://annenberg.net/courses/landingPage.php?courseID=61030" rel="noopener noreferrer">https://annenberg.net/courses/landingPage.php?courseID=61030</a></p>

Introduction and Key Takeaways

Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications.

Share Introduction and Key Takeaways

Sign up to save your podcasts

Introduction and Key Takeaways

Introduction and Key Takeaways